According to Takara, the workflow allows researchers to use 25 percent of the primers and enzymes required by conventional single-cell methods.
The preliminary revenue results come ahead of the company's planned merger with Takara Bio USA Holdings.
The deal is expected to help Takara Bio Group expand its presence in next-generation sequencing library preparation and other markets.
The deal is expected to broaden Takara's portfolio of products for next-generation sequencing library preparation and genetic analysis.
The firm recently enacted a 1-for-5 reverse stock split to help its shares meet the minimum bid price requirement for listing on the market.
The firm said the one-for-five reverse split will help address a looming delisting from the Nasdaq Capital Market by boosting the bid price per share above $1.00.
The company recently urged shareholders to approve the deal, saying the cash consideration they'd receive would represent a premium over recent stock prices.
The firm said it is on track to meet the full-year consolidated revenues that it needs in order to satisfy the terms of its pending merger with Takara Bio USA.
The institute has selected the firm's RNA-seq library preparation kits for use in gene expression profiling in single-cell analysis of brain cells.
The single-cell analysis firm told shareholders that while the final offer from Takara is not set in stone, they're unlikely to be offered better terms.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.